Prevention of transthyretin arnyloid disease by changing protein misfolding energetics

Science

Volumn 299, Issue 5607, 2003, Pages 713-716

  Hammarström, Per ^a   Wiseman, R Luke ^a   Powers, Evan T ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLOMERATION; GENES; PROTEINS;

AMYLOID FIBRIL FORMATION;

DISEASES;

AMYLOID; METHIONINE; PREALBUMIN; THREONINE; PROTEIN SUBUNIT;

ENERGETICS; GENETICS; PROTEIN;

AMYLOIDOSIS; ARTICLE; ENERGY TRANSFER; FAMILIAL DISEASE; GENE MUTATION; KINETICS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; CHEMISTRY; DRUG ANTAGONISM; GENE REPRESSION; GENETICS; HUMAN; METABOLISM; PH; PROTEIN DENATURATION; PROTEIN QUATERNARY STRUCTURE; THERMODYNAMICS;

AMYLOIDOSIS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; PREALBUMIN; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; SUPPRESSION, GENETIC; THERMODYNAMICS;

EID: 0037473750     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1079589     Document Type: Article

References (34)

1. C. M. Dobson, Trends Biochem. Sci. 24, 329 (1999).
2. A. L. Fink, Folding Des. 3, R9 (1998).
3. D. J. Selkoe, Science 275, 630 (1997).
4. M. S. Goldberg, P. T. Lansbury Jr., Nature Cell Biol. 2, E115 (2000).
5. J. W. Kelly, Curr. Opin. Struct. Biol. 6, 11 (1996).
6. D. R. Jacobson, J. N. Buxbaum, Adv. Hum. Genet. 20, 69 (1991).
7. T. Coelho et al., J. Rheumatol. 20, 179 (1993).
8. T. Coelho et al., Neuromuscular Disord. 6, 27 (1996).
9. P. Hammarström, F. Schneider, J. W. Kelly, Science 293, 2459 (2001).
10. Supporting material is available on Science Online.
11. P. Hammarström, X. Jiang, A. R. Hurshman, E. T. Powers, J. W. Kelly, Proc. Natl. Acad. Sci. U.S.A. 99, 16427 (2002).
12. S. L. McCutchen, Z. Lai, G. Miroy, J. W. Kelly, W. Colon, Biochemistry 34, 13527 (1995).
13. X. Jiang, J. N. Buxbaum, J. W. Kelly, Proc. Natl. Acad. Sci. U.S.A. 98, 14943 (2001).
14. J. C. Sacchettini, J. W. Kelly, Nature Rev. Drug Discovery 1, 267 (2002).
15. G. J. Miroy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 15051 (1996).
16. Small-molecule inhibitors 6 and 8 through 10 do not inhibit TTR amyloidosis when a monomeric variant of TTR (M-TTR) (24) is employed for acid-mediated amyloid fibril formation studies (Fig. 2F), demonstrating that the inhibitors mediate amyloid inhibition through tetramer binding (Fig. 2, E and F). Inhibitor 7 slightly inhibits fibril formation from M-TTR because it drives a small fraction of M-TTR into a tetrameric quaternary structure (Fig. 2F).
17. T. Klabunde et al., Nature Struct. Biol. 7, 312 (2000).
18. 2) ligands were all evaluated under physiological conditions (Fig. 1B), and the experiments described here were carried out in 6 M urea.
19. d2)}.
20. J. V. Schloss, Acc. Chem. Res. 21, 348 (1988).
21. D. Baker, J. L. Sohl, D. A. Agard, Nature 356, 263 (1992).
22. P. Hammarström, X. Jiang, S. Deechongkit, J. W. Kelly, Biochemistry 40, 11453 (2001).
23. Sc).
24. X. Jiang et al., Biochemistry 40, 11442 (2001).
25. J. Ma, S. Lindquist, Science 298, 1785 (2002); published online 17 October 2002 (10.1126/science. 1073619).
26. D. M. Walsh et al., Nature 416, 535 (2002).
27. M. Bucciantini et al., Nature 416, 507 (2002).
28. H. A. Lashuel et al., Nature 418, 291 (2002).
29. W. L. Klein et al., Trends Neurosci. 24, 219 (2001).
30. V. B. Oza et al., J. Med. Chem. 45, 321 (2002).
31. S. A. Peterson et al., Proc. Natl. Acad. Sci. U.S.A. 95, 12956 (1998).
32. H. E. Purkey, J. W. Kelly, unpublished results.
33. H. E. Purkey, M. I. Dorrell, J. W. Kelly, Proc. Natl. Acad. Sci. U.S.A. 98, 5566 (2001).
34. We thank NIH (grant DK 46335), The Skaggs Institute of Chemical Biology, and the Lita Annenberg Hazen Foundation for financial support; R. A. Lerner and I. Wilson for useful suggestions; and the Wenner-Gren Foundation for a postdoctoral fellowship (P.H.).